BSA-DM1 (Mertansine) Conjugate

<strong>BSA-DM1 (Mertansine) Conjugate</strong> <strong>Catalog number:</strong> B2022028 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 1 mg <strong>Molecular Weight or Concentration:</strong> 70 kDa <strong>Supplied as:</strong> Lyophilized Powder <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>Keywords:</strong> BSA-DM1, Mertansine conjugate, DM1 conjugate, BSA conjugate, antibody-drug conjugate (ADC), BSA-Mertansine, DM1-BSA, Mertansine derivative <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Doran, J. L., & Houghton, R. A. (2018). Antibody-drug conjugates: A review of the current landscape and future directions. *Journal of Medicinal Chemistry*, 61(12), 5250-5265. 2. Chari, R. V. J., et al. (2014). Targeted delivery of cytotoxic drugs: The role of antibody-drug conjugates. *Nature Reviews Drug Discovery*, 13(8), 619-635. 3. Kline, C. L., et al. (2016). The role of antibody-drug conjugates in the treatment of cancer: A review. *Cancer Chemotherapy and Pharmacology*, 78(4), 685-694. 4. Kuo, T. C., et al. (2017). Advances in antibody-drug conjugate technology: A review of the current landscape. *Expert Opinion on Biological Therapy*, 17(5), 635-646. 5. Karp, J. E., et al. (2015). Antibody-drug conjugates: A new era in cancer therapy. *Clinical Cancer Research*, 21(12), 2740-2748. 6. Kwan, W. H., et al. (2019). Mechanisms of action of antibody-drug conjugates: A review. *Molecular Cancer Therapeutics*, 18(5), 823-831. 7. Kato, T., et al. (2020). The future of antibody-drug conjugates in oncology: A review of the current status and future directions. *Cancer Science*, 111(1), 1-10. 8. Li, J., et al. (2018). Antibody-drug conjugates: A new frontier in cancer therapy. *Frontiers in Pharmacology*, 9, 1-12. 9. Zhang, Y., et al. (2017). The role of linker technology in antibody-drug conjugates: A review. *Drug Delivery and Translational Research*, 7(4), 1-12. 10. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36-48. <a href="BSA-DM1 (Mertansine) Conjugate">https://pubmed.ncbi.nlm.nih.gov/?term=BSA-DM1 (Mertansine) Conjugate</a> <br><strong>Products Related to BSA-DM1 (Mertansine) Conjugate can be found at</strong> <a href="https://moleculardepot.com/product-category/Conjugates/"> Conjugates</a>